The Wall Street Journal Reports on November 5, 2013 on Johnson & Johnson’s $2.2 Billion Settlement of Criminal and Civil Claims of Fraud In Promoting Drugs, Including Risperdal

November 12th, 2014

Stone & Magnanini represented whistleblowers in civil actions for False Claims Act violations, against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., for fraud in promoting drugs, including Risperdal. As reported in the Wall Street Journal, Johnson & Johnson agreed to pay $2.2 billion to settle criminal and civil claims in connection with the fraud.

Jonathan D. Rockoff, J&J Pays $2.2 Billion to Settle Probe, WALL ST. J., Nov. 5, 2013.